NorthWest Biotherapeutics Inc (NWBO)

[notbrad]

This is the key statement:

The Company has adopted a policy of recognizing these payments as revenue when received. As opposed to accruing revenues. This is why we don't see revenues from HE in the 10-Q.

The quarterly filings at least for the past year have also stated that operating costs include costs related to early access programs in Europe.

Also, someone on this board had emailed PEI last week and received a response acknowledging that HE for L is alive and well and available to patients. Agreed that this has not been validated.

So, the question is why haven't we received payment yet? This is just my guess: NWBO probably asked for a price in line with other similar treatments and the German hospitals have balked, probably saying that this is not yet an approved treatment. Maybe they have reached an agreement to wait till there are definitive results from the phase III. It's a risk that LP is taking. But she is probably also concerned that any pricing established in Europe may impact US pricing. In the end she may not get paid at all if the trial fails. But the fact that she is willing to wait (which is a big risk and she could use the money now even if the payment is lower) makes me believe that she must be very very confident in the outcome. JMHO.